In a Japanese observational study, which assessed the prevalence, treatment pattern, and long-term risk of hyperkalemia in real-world clinical practice, hyperkalemia prevalence was 67.9 per 1000 and increased in patients with chronic kidney disease (CKD), heart failure and renin–angiotensin–aldosterone system inhibitors (RAASi) use. The gene discussed is REN; the disease is chronic kidney disease.